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The possibility was examined that inhibition of growth of PY8 15 mouse mastocytoma cells by N6,02’-dibu- 
tyryladenosine 3’,5’-cyclic monophosphate (DB cyclic AMP) results from inhibition of c-myc gene expres- 
sion. Temporary increases in c-myc RNA which occurred soon after DB cyclic AMP treatment and upon 
removal of the drug were not consistent with direct inhibition of c-myc gene expression by DB cyclic AMP. 
The increases in c-myc RNA coincided with the passage through, or accumulation of cells in late G, - early 
S phase. It is proposed that cyclic AMP may stimulate c-myc gene expression which normally occurs only 
in late G, - early S phase in PY815 cells and that cyclic AMP prevents c-myc expression in cells at other 
phases of the cell cycle by inhibiting their progression past a cyclic AMP-sensitive restriction point in early 
G, phase. 
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1. INTRODUCTION 
Adenosine 3 ’ ,5 ’ -cyclic monophosphate (cyclic 
AMP) has been implicated as a regulator of mam- 
malian cell growth [l-3]. With PY815 mouse 
mastocytoma cells we have shown that the cyclic 
AMP analogue N6,02 ’ -dibutyryladenosine 3 ’ ,5 ’ - 
cyclic monophosphate (DB cyclic AMP) increases 
the intracellular concentration of cyclic AMP and 
inhibits growth by slowing progression past a 
cyclic AMP-sensitive point in the Gi phase of the 
cell cycle [4-61. After removing DB cyclic AMP 
the growth-arrested PY815 cells require 2-3 h to 
become insensitive to readdition of DB cyclic AMP 
and progress into their normal 9-10 h cell cycle 
[5]. The initiation of growth of Gi phase-arrested 
cells has recently been shown to involve the expres- 
sion of growth-related genes or oncogenes [7-91. 
Therefore it was possible that cyclic AMP might 
reduce the expression of specific oncogenes, to 
regulate PY815 cell growth. To test this hypothesis 
we examined the effect of inhibiting PY815 cell 
growth with DB cyclic AMP on the availability of 
c-myc RNA in PY815 cells. Our results indicate 
that DB cyclic AMP does not inhibit PY815 cell 
growth by decreasing c-myc RNA. Instead, c-myc 
RNA increased in a cell cycle-dependent manner 
which may be affected by cyclic AMP according to 
the position of cells within the cell cycle. 
2. MATERIALS AND METHODS 
PY815 mouse mastocytoma cells were grown as 
described [5]. The v-myc gene was provided by Dr 
A. Reeve (Biochemistry Department, Otago 
University, New Zealand) as a 1,5 kilobase DNA 
fragment cloned into the PstI site of pBR322 [IO]. 
Total cellular RNA was prepared from 7 x 10’ 
PY815 cells washed once with phosphate-buffered 
saline and recovered by centrifugation. The cells 
were resuspended at 2°C in lysis mixture (0.14 M 
NaCI, 1.5 mM MgC12, 10 mM Tris-HCI (pH 8.6), 
0.5% Nonidet NP40, 10 mM vanadyl-ribonu- 
cleoside complexes) vortex-mixed for 10 s then 
underlayered with an equal volume of lysis mixture 
containing 24% sucrose and 1% NP40. After 
5 min the lysate was centrifuged at 10000 x g for 
2 min at 4°C in a swinging bucket rotor and the 
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upper layer of cytoplasmic material was recovered 
and mixed with an equal volume of 0.3 M NaCl, 
2% SDS, 25 mM NazEDTA, 0.2 M Tris-HCl (pH 
7.5). Proteinase K (200 pg/ml) was then added and 
the cytoplasmic extracts were incubated for 30 min 
at 37°C. Finally, the mixture was extracted several 
times with phenol : chloroform (1 : 1, v/v) and after 
centrifugation RNA in the aqueous phase was 
recovered by precipitation with 2 vols ethanol at 
-20°C. The RNA precipitates were recovered by 
centrifugation, washed once with 75% ethanol, 
0.1 M Na acetate (pH 5.2), redissolved in 0.1 M 
Na acetate (pH 6), then phenol extracted at 60°C 
to ensure total protein removal [l 11. 
To clone the v-myc gene into the phage Ml3mp8 
DNA vector the 1.5 kilobase-pair v-myc DNA 
fragment was excised from the pBR322 v-myc 
hybrid with the restriction enzyme Pstl and 
recovered by agarose gel electrophoresis followed 
by electroelution [12]. The v-myc DNA (100 ng) 
was then ligated into the Pstl site of phage 
M13mp8 DNA (20 ng) in a final volume of 10 ~1 
containing 1 mM ATP, 10 mM MgCl2, 10 mM 
dithiothreitol, 66 mM Tris-HCl (pH 7.6) and 0.1 
units of T4 DNA ligase at 14°C overnight. The 
ligated DNA was transformed into competent E. 
coli JM 101 [ 131. Transformed bacteria containing 
recombinant phage M 13mp8 DNA were selected 
by plating aliquots of transformed cells in soft agar 
containing 0.2 ml of exponential phase E. coli 
JMlOl, 40~1 of 100 mM isopropyl thiogalac- 
toside, 40~1 of 2% X-gal in dimethylformamide 
onto YT agar plates. The plates were incubated at 
37°C for 12 h when recombinant phage replication 
produced clear plaques due to the v-myc DNA in- 
serts placing the fl-galactosidase gene out of phase 
with its promoter. 
Single-stranded phage DNA was prepared from 
recombinant Ml3mp8 phage as described [14] and 
checked for v-myc DNA inserts by agarose gel elec- 
trophoresis (0.7% agarose in borate buffer). 
Recombinant M13mp8 phage DNA containing v- 
myc DNA showed reduced mobility on agarose 
gels. To identify clones with complementary v-myc 
DNA strands and ensure the transcribed strand of 
v-myc DNA was cloned, template DNAs contain- 
ing inserts were screened by hybridising all 
M13mp8 DNAs (0.5 pg) to a single recombinant 
M13mp8 DNA in 1011 of 10 mM NaCl, 1 mM 
MgCl2, 1 mM dithiothreitol, 5 mM Tris-HCl (pH 
14 
7.5). The DNA was denatured at 95°C and an- 
nealed by slow cooling to 20°C. Complementary 
phage template DNAs were distinguished from 
non-complementary phage template DNA by their 
reduced mobility in 0.7% agarose-borate buffer 
gels. To identify which clones carried the tran- 
scribed (+) strand of v-myc DNA the first 60 
nucleotides of two complementary phage template 
DNAs were sequenced as described by Sanger et al. 
[ 151. The recombinant Ml3mp8 DNA containing 
the (+) strand of v-myc was used to prepare a v- 
myc DNA hybridisation probe. 
A high specific activity v-myc DNA probe (1 x 
10’ cpm 32P per pg DNA) was synthesized by 
reverse priming the v-myc (+) template DNA 
using the method of Hu and Messing [16]. The 
New England Nuclear 13-nucleotide oligomer 120 1 
was used as primer. The primer was annealed and 
extended as described by Meinkoth and Wahl [ 171. 
To detect c-myc RNA transcripts samples of 
total cellular RNA isolated from 1 x lo6 cells at 
various times during and after drug treatment were 
resuspended in 10~1 of 0.75 M NaCl, 0.075 M 
Na3+ citrate, 7% formamide and denatured at 60°C 
for 15 min. The cellular RNA was then dotted on- 
to nitrocellulose filters previously washed with 3 M 
NaCl, 0.3 M Naf citrate. The filters were baked, 
prehybridized and hybridized with the v-myc( +) 
probe as described [17]. Finally, the filters were 
washed 3 times with 15 mM NaCl, 1.5 mM Na; 
citrate, 0.1% SDS at 20°C for 5 min and with 
1.5 mM NaCl, 0.15 mM Na: citrate, 0.1% SDS at 
50°C until all background radioactivity was 
removed. The hybridized ‘dots’ were then cut out 
and associated Cerenkov radiation was measured 
in a liquid scintillation counter. 
Cell cycle distributions were measured using an 
Ortho ICP-22A microfluorimeter after staining 
DNA with diamphinophenylindole. 
3. RESULTS AND DISCUSSION 
Initial attempts to detect c-myc gene expression 
in PY815 cells using a ‘nick translated’ v-myc 
DNA probe (spec. act. 5 x lo6 cpm 32P/,ug DNA) 
prepared from the 1.5 kilobase-pair v-myc gene ac- 
cording to the method of Rigby et al. [ 181 were un- 
successful. These v-myc probes were probably 
unable to detect a single messenger RNA species 
within a mixture of total cellular RNA due to their 
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low specific activity. Therefore, a probe with much 
higher specific radioactivity was prepared by clon- 
ing a I.5 kilobase-pair fragment of DNA contain- 
ing the v-myc gene into the phage gene vector 
M13mp8. 
Recombinant M13mp8 DNAs were screened in- 
itially to detect clones containing complementary 
sequences by hybridizing a single clone to all other 
clones. Then the first 60 nucleotides of two com- 
plementary recombinant M13mp8 clones were se- 
quenced to identify the clone containing the ( +) 
sense transcribed strand of v-myc (cf. [19]). The 
Ml 3mp8 v-myc clone containing the ( + ) strand of 
v-myc was used to make a radioactive probe by 
primer extension in the presence of [32P]dCTP. 
Probes synthesised by this technique (spec. act. 1 
x lo8 cpm perpug DNA) were used to detect c-myc 
gene expression by Northern dot-blot hybridisa- 
tion. Probes were hybridised to total cellular RNA 
prepared from untreated PY815 cells, cells grown 
for 3, 6, 9, 12 and 15 h with 0.1 mM DB cyclic 
AMP + 1 mM theophylline and cells treated with 
drug for 15 h then transferred to drug-free 
medium for 3, 6, 9 and 12 h. 
Fig.lA shows that 3 h after treating PY815 cells 
with DB cyclic AMP and theophylline the level of 
c-myc gene expression had increased 1.8-fold. 
However, this increase was not sustained despite 
the continued presence of DB cyclic AMP and 
theophylline for up to 15 h and between 6 and 15 h 
c-myc expression was reduced to half that in un- 
treated cells. Three hours after removing the drugs 
c-myc expression again increased briefly to 
1.5-fold that in untreated cells before decreasing 
again to low levels. These results showed no cor- 
relation between the availability of DB cyclic AMP 
and theophylline and c-myc RNA. 
Other researchers have suggested that c-myc 
gene expression is associated with the Gi phase of 
the cell cycle [7,8,20]. Therefore, we analysed the 
distribution of PY815 cells within the cell cycle at 
various times during and following treatment with 
DB cyclic AMP and theophylline, to determine 
whether the level of c-myc RNA was cell cycle 
related under the conditions of our experiments. 
Fig.lB shows that the peaks of c-myc RNA that 
occurred during DB cyclic AMP treatment, or 
when DB cyclic AMP was removed, corresponded 
to times when the majority of cells were present in 
late Gi or early S phase of the cell cycle, rather 
6 G, 
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403 
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6 12 18 24 30 
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Fig.1. (A) Detection of c-myc RNA in total PY815 cell 
RNA by Northern dot-blot analysis. Hybridised “P- 
labelled v-myc DNA was measured at various times after 
adding DB cyclic AMP + theophylline to cultures and 
after transferring drug treated cells to drug-free medium 
after 15 h (arrowed). (B) Cell cycle distribution at 
various times after adding DB cyclic AMP + 
theophylline to cultures and after transferring drug- 
treated cells to drug-free medium at 15 h (arrowed). 
than to the availability of DB cyclic AMP and 
theophylline. 
The preceding results do not support the idea 
that inhibition of PY815 cell growth by cyclic 
AMP is a consequence of inhibition of c-myc gene 
expression. In fact, c-myc RNA increased, when 
cells were treated with DB cyclic AMP and 
15 
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theophylline and again soon after the drugs were 
removed. These increases in c-myc RNA occurred 
when the majority of cells resided in late GI or ear- 
ly S phase, beyond the cyclic AMP-sensitive 
restriction point in early GI phase of the PY815 cell 
cycle [5,6]. Thus the increases in c-myc RNA ap- 
peared to be associated with the movement of cells 
out of GI into S phase. c-myc RNA eventually 
decreased below that in untreated log phase cells 
when cells accumulated at the cyclic AMP-sensitive 
point in early GI phase (fig.lA and B). 
These observations would be consistent with the 
proposal that DB cyclic AMP stimulates the nor- 
mal increase in c-myc RNA that occurs in PY815 
cells beyond the cyclic AMP-sensitive restriction 
point in GI phase. In addition cyclic AMP would 
prevent other cells from passing the cyclic AMP- 
sensitive restriction point and increasing c-myc 
RNA production in late Gl-early S phase. This 
would occur if c-myc expression is normally con- 
fined to a period in late G1-early S phase [8,20] 
and stimulated by cyclic AMP. 
While our research was in progress Huang and 
Cho-Chung [21] reported that hormone 
withdrawal or DB cyclic AMP suppresses the c- 
ras” oncogene in rat mammary carcinomas. 
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